Kyverna Therapeutics, Inc. Investment Income, Interest
Kyverna Therapeutics, Inc. (KYTX) reported Investment Income, Interest of $1.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Kyverna Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $1.93M, a 18.40% decline year-over-year.
- Kyverna Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $2.33M, a 17.63% decline year-over-year.
- Kyverna Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.91M, a 46.71% decline year-over-year.
- Kyverna Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $2.00M, a 54.08% decline year-over-year.
- Kyverna Therapeutics, Inc. investment income, interest for fiscal 2025 was $9.09M, a 40.79% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. investment income, interest for fiscal 2024 was $15.36M, a 573.05% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. investment income, interest for fiscal 2023 was $2.28M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.93M 10-Q · filed 2026-08-11 | $4.26M 10-Q · filed 2026-08-11 | $6.16M derived: sum of 3 quarters · filed 2026-08-11 | $8.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.33M 10-Q · filed 2026-05-12 | $4.23M derived: sum of 2 quarters · filed 2026-05-12 | $6.23M derived: sum of 3 quarters · filed 2026-05-12 | $8.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.90M derived: sum of 2 quarters · filed 2026-03-26 | $6.27M derived: sum of 3 quarters · filed 2026-08-11 | $9.09M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-12 | $4.36M derived: sum of 2 quarters · filed 2026-08-11 | $7.19M 10-Q · filed 2025-11-12 | $10.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.36M 10-Q · filed 2026-08-11 | $5.19M 10-Q · filed 2026-08-11 | $8.76M derived: sum of 3 quarters · filed 2026-08-11 | $13.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.83M 10-Q · filed 2026-05-12 | $6.40M derived: sum of 2 quarters · filed 2026-05-12 | $10.76M derived: sum of 3 quarters · filed 2026-05-12 | $15.45M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.93M derived: sum of 2 quarters · filed 2026-03-26 | $12.62M derived: sum of 3 quarters · filed 2026-03-26 | $15.36M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.36M 10-Q · filed 2025-11-12 | $9.05M derived: sum of 2 quarters · filed 2025-11-12 | $11.78M 10-Q · filed 2025-11-12 | $12.57M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.69M 10-Q · filed 2025-08-12 | $7.43M 10-Q · filed 2025-08-12 | $8.22M derived: sum of 3 quarters · filed 2025-08-12 | $9.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.73M 10-Q · filed 2025-05-13 | $3.52M derived: sum of 2 quarters · filed 2025-05-13 | $4.40M derived: sum of 3 quarters · filed 2025-05-13 | $4.67M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $789.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.67M derived: sum of 2 quarters · filed 2025-03-27 | $1.93M derived: sum of 3 quarters · filed 2025-03-27 | $2.28M 10-K · filed 2025-03-27 |
| 2023-09-30 | $880.00K 10-Q · filed 2024-11-13 | $1.14M derived: sum of 2 quarters · filed 2024-11-13 | $1.49M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $264.00K 10-Q · filed 2024-08-12 | $613.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $349.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |